Immuron Ltd (ASX: IMC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immuron Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $36.36 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 224.10 million
Earnings per share -0.034
Dividend per share N/A
Year To Date Return -30.43%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Immuron Ltd (ASX: IMC)
Latest News

IMC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Immuron Ltd

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
09 Feb 2021 Ravi Savarirayan Exercise 900 $207,000
Exercise of options.
09 Feb 2021 Ravi Savarirayan Buy 409 $94,090
Exercise of options.
20 Nov 2020 Daniel Pollock Sell 100 $26,000
On-market trade.
13 Nov 2020 Stephen Anastasiou Issued 1 $459,000
Issue of securities. As per announcement on 17/11/2020.
13 Nov 2020 Stephen Anastasiou Issued 468 $37,500
Issue of securities.
13 Nov 2020 Peter Anastasiou Issued 468 $37,500
Issue of securities.
13 Nov 2020 Peter Anastasiou Issued 1 $459,000
Issue of securities. As per announcement on 17/11/2020.
13 Nov 2020 Ravi Savarirayan Issued 468 $37,500
Issue of securities.
13 Nov 2020 Ravi Savarirayan Issued 1 $459,000
Issue of securities. As per announcement on 17/11/2020.
13 Nov 2020 Roger Aston Issued 712 $57,000
Issue of securities.
13 Nov 2020 Roger Aston Issued 1 $459,000
Issue of securities. As per announcement on 17/11/2020.
13 Nov 2020 Daniel Pollock Issued 618 $49,500
Issue of securities.
13 Nov 2020 Daniel Pollock Sell 100 $27,000
On-market trade.
13 Nov 2020 Daniel Pollock Sell 29 $7,517
Off-market trade.
13 Nov 2020 Daniel Pollock Buy 29 $7,517
Off-market trade.
13 Nov 2020 Daniel Pollock Issued 1 $459,000
Issue of securities.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Roger Aston Non-Executive ChairmanNon-Executive Director May 2012
Dr Aston has more than 20 years experience in the pharmaceutical and biotechnology industries. Prior to his position at Mayne Pharma, some of his previous positions have included chief executive officer of Peptech Limited (ASX: PTD), director of Cambridge Antibody Technology Limited (LSE: CAT and NASDAQ: CATG) and chairman of Bio Focus Plc (formerly: Cambridge Drug Discovery Limited). Dr Aston was also founder and chief executive officer of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr Aston has been involved in the development of many pharmaceutical and biotechnology companies. He has experience including negotiating global licence agreements, overseeing product registration activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures. He is member of risk committee.
Mr Daniel Pollock Non-Executive Director Oct 2012
Mr Pollock is a sole practitioner in his own legal firm based in Melbourne which operates internationally and specialises in commercial law. Further, he is executive director and co-owner of Great Accommodation Pty Ltd, a property management business operating in Victoria. Mr Pollock has had historical involvement as a seed investor and board member of a number of small unlisted companies. The most recent of these was an e-pharmacy company where he was heavily involved in its commercial growth and ultimate sale to a large listed health services company. He is chair of risk committee.
Mr Stephen Anastasiou Non-Executive Director May 2013
Mr Anastasiou has over 20 years experience in general management, marketing and strategic planning within the healthcare industry. His experience incorporates medical diagnostics, pharmaceuticals, hospital, dental and over-the-counter products, with companies including the international pharmaceutical company Bristol-Myers Squibb (NYSE: BMY). While working with KPMG Peat Marwick as a management consultant, Mr Anastasiou has previously led project teams in a diverse range of market development and strategic planning projects in both the public and private sector. He is also a director and shareholder of a number of unlisted private companies, covering a variety of industry sectors that include healthcare and funds management. Mr Anastasiou's companies have participated in several corporate transactions involving business units and brands of multinational and Australian companies.
Mr Peter Anastasiou Executive DirectorVice Chairman May 2015
Mr Anastasiou is a serial entrepreneur and investor with experience in business in Australia and internationally. Over the past 25 years, he has been credited with rebuilding a number of companies through the implementation of various corporate restructurings, acquisitions and solid financial management practices, with his most recent success being managing the restructuring of SABCO to ensure the future of this 100-year-old iconic Australian company. Mr Anastasiou's involvement with Immuron commenced in May 2013 following his substantial underwriting support of the group's renounceable rights issue, which was surpassed by his further funding support of the $9.66 million (before costs) capital raising in February 2014 resulting in an ownership of approximately 15 percent of the company via his associated investment funds. Mr Anastasiou was the founding chairman of the ACSI Group of Companies, which has owned and managed successful consumer companies such as SABCO, Britex Carpet Care, Rug Doctor and Crystal Clear. Mr Anastasiou also has a number of philanthropic interests including being a patron of the Identity Theatre for men, a prior board member and supporter of the Indigenous Eye Health Unit at Melbourne University, a supporter of the John Fawcett Foundation in Bali, and a founding investor and director of Melbourne Victory Football Club.
Mr Ravi Savarirayan Non-Executive Director Apr 2017
Prof Savarirayan has been a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as professor and research group leader of skeletal biology and disease at the Murdoch Children's Research Institute since September 2000. Prof Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium since January 2011 and has been the chair of the specialist advisory committee in clinical genetics at the Royal Australasian College of Physicians since February 2009. He was president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several international working committees on constitutional diseases of bone. Prof. Savarirayan's primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis and he leads numerous clinical therapy trials for these conditions. He has published over 180 peer-reviewed articles, collaborating with peers from over 30 countries. He has been on the editorial board of Human Mutation since January 2009, European Journal of Human Genetics since July 2007, American Journal of Medical Genetics since December 2011 and the Journal of Medical Genetics since June 2005. He was recently named one of the "Brilliant Minds" of the Murdoch Children's Research Institute over the past 30 years.
Mr Phillip Hains Chief Financial OfficerCompany Secretary Apr 2013
-
Dr Jerry Kanellos Chief Executive Officer Mar 2020
-
Jerry Kanellos Chief Executive Officer
-
Phillip Hains Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 104,631,009 46.57%
Grandlodge Pty Ltd And Its Related Holdings 11,778,269 5.26%
Authentics Australia Pty Ltd <Authentics Australia A/C> 7,500,000 3.35%
Dr Russell Kay Hancock 3,000,000 1.34%
Mr Stephen Anastasiou & Mrs Andria Anastasiou <Anastasiou Family S/F A/C> 2,494,746 1.11%
Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C> 2,000,000 0.89%
Citicorp Nominees Pty Limited 1,719,277 0.77%
Mr Anthony Frederick Wallace Hyett 1,350,000 0.60%
Anne Pattison Pty Ltd <Aep No 3 A/C> 1,345,000 0.60%
Mr William David Frank Bird 1,300,000 0.58%
Inverarey Pty Ltd <The Kilchurn A/C> 1,050,000 0.47%
Texas Woods Pty Ltd <The Plush Family A/C> 978,393 0.44%
Mr Nick Karopoulos 950,000 0.42%
Hadasit Medical Research Services & Development Ltd 887,462 0.40%
Peppertree Custodian Services Pty Ltd <Mulcahy Superannuation A/C> 860,634 0.38%
South Bay Nominees Pty Ltd <C & P Hong Family A/C> 850,000 0.38%
Mr David Anthony Plush & Mrs Ann Louise Plush <Plush Super Fund A/C> 834,075 0.37%
Mrs Rochelle Jane Pattison & Ms Katherine Margaret Forrest <Sylvan S/F A/C> 800,000 0.36%
Advance Publicity Pty Ltd <The Izmar Family A/C> 750,000 0.33%

Profile

since

Note